Could Infinity Pharmaceuticals Inc (NASDAQ:INFI) Go Down After Its Newest Short Interest Report?

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Logo

Investors sentiment decreased to 0.75 in Q2 2019. Its down 0.53, from 1.28 in 2019Q1. It dived, as 10 investors sold Infinity Pharmaceuticals, Inc. shares while 10 reduced holdings. 7 funds opened positions while 8 raised stakes. 30.53 million shares or 1.07% less from 30.86 million shares in 2019Q1 were reported.
Meeder Asset Management Inc invested 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). State Bank Of America Corporation De accumulated 1,500 shares. Wells Fargo And Mn owns 0% invested in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) for 48,461 shares. The New York-based Community Bancorp Na has invested 0.01% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Moreover, Qs Investors Lc has 0% invested in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) for 153,550 shares. Renaissance Technologies Lc stated it has 0% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Aperio Group Limited Company has invested 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Connor Clark Lunn Management Limited owns 32,169 shares. Fosun International Ltd has 0.05% invested in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Wellington Mngmt Group Limited Liability Partnership holds 1.56M shares. Amer Grp invested in 20,000 shares or 0% of the stock. The New York-based First Eagle Invest Ltd Liability Co has invested 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Geode Cap Mgmt holds 0% or 363,617 shares in its portfolio. Vanguard Group Inc invested 0% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Platinum Invest Management Limited, a Australia-based fund reported 1.14M shares.

The stock of Infinity Pharmaceuticals Inc (NASDAQ:INFI) registered a decrease of 0.47% in short interest. INFI’s total short interest was 252,300 shares in September as published by FINRA. Its down 0.47% from 253,500 shares, reported previously. With 89,700 shares average volume, it will take short sellers 3 days to cover their INFI’s short positions.

The stock decreased 2.44% or $0.03 during the last trading session, reaching $1.2. About 43,745 shares traded. Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has declined 15.52% since September 13, 2018 and is downtrending. It has underperformed by 15.52% the S&P500.

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. The company has market cap of $71.31 million. The Company’s lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma is in Phase 1 clinical study. It currently has negative earnings. The firm has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib.

More notable recent Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) news were published by: Seekingalpha.com which released: “Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q1 2019 Results – Earnings Call Transcript – Seeking Alpha” on May 07, 2019, also Streetinsider.com with their article: “Infinity Pharma (INFI) Begins Two Clinical Trials Evaluating IPI-549 in Novel Triple Combination Therapies for Treatment of Solid Tumors – StreetInsider.com” published on September 04, 2019, Nasdaq.com published: “Why Infinity Pharmaceuticals (INFI) Could Shock the Market Soon – Nasdaq” on April 12, 2018. More interesting news about Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) were released by: Benzinga.com and their article: “The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings – Benzinga” published on July 30, 2019 as well as Nasdaq.com‘s news article titled: “Infinity (INFI) Up 6% Since Last Earnings Report: Can It Continue? – Nasdaq” with publication date: June 06, 2019.

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.